Laura von Schantz
4PUBLICATIONS
40CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Sep 10, 2025
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade.Hampus Andersson, Ida Uddbäck, Tova Hermodsson
|Mar 26, 2024
RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties.Barnabas Nyesiga, Mattias Levin, Anna Säll
|Oct 05, 2023
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.Karin Enell Smith, Sara Fritzell, Anneli Nilsson
|Nov 07, 2022
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.Michelle H Nelson, Sara Fritzell, Robert Miller
Pageof 1
Frequent Collaborators
4 joint publications
Sara Fritzell
3 joint publications
Anna Säll
3 joint publications
Peter Ellmark
2 joint publications
Mattias Levin
2 joint publications
Anneli Nilsson
2 joint publications
Karin Hägerbrand
2 joint publications
Lill Ljung
2 joint publications
Anette Sundstedt
2 joint publications
Laura A Varas
1 joint publications
Michelle H Nelson
